07:36 AM EDT, 04/21/2026 (MT Newswires) -- Compass Pathways (CMPS) said Tuesday it has entered a collaboration with Osmind to help small- and mid-sized psychiatry clinics prepare for the potential rollout of psychedelic therapies in the US.

The partnership will focus on defining the clinical, operational and infrastructure requirements for delivering Compass'investigational COMP360 therapy in real-world settings, with Osmind's network of over 1,000 psychiatry clinics providing insights to help develop scalable care model.

The collaboration aims to help independent practices adopt innovative mental health treatments while maintaining high standards of safety, access, and clinical quality, the companies said.

Shares of Compass Pathways were up 3.7% in Tuesday's premarket activity.